AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
OKYO Pharma reports positive results from Phase 2 neuropathic corneal pain trial, potential for nerve restoration with urcosimod.
ByAinvest
Friday, Dec 12, 2025 2:00 am ET1min read
OKYO Pharma's Phase 2 trial for neuropathic corneal pain (NCP) showed favorable outcomes with its investigational therapy urcosimod. Patients receiving 0.05% urcosimod showed increases in total nerve fiber count and length, while the placebo group showed decreases. The data suggest a potential positive effect of urcosimod on corneal nerve health in NCP patients, and the company believes it may open a new therapeutic avenue for patients with NCP. Shares of OKYO added 9.4% in Thursday morning trading.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet